A consortium of six partners has a single goal: the development and evaluation of a vaccine for the prevention of Rift Valley fever in humans. The project is named "LARISSA", acronym for Live Attenuated Rift Valley Fever Vaccine for Single Shot Application. ​​​LARISSA will manufacture and validate a vaccine for the prevention of Rift Valley fever in humans. The project encompasses vaccine manufacturing, preclinical research, and a Phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose of the vaccine.

​